EUVIMEDEUVIMED entdecken
Crossref

Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis

Dana V Rizk, Jonathan Barratt, Yusuke Suzuki, Hong Zhang, Muh Geot Wong, Adrian Liew, Richard Lafayette, Vladimír Tesař, Hernán Trimarchi, Kevin Carroll, Ian S D Roberts, Vivekanand Jha iD und 14 weitere

New England Journal of Medicine · 22.10.2026

DOI: 10.1056/nejmoa2609127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift New England Journal of Medicine, online erschienen am 22.10.2026. Verfasst von Dana V Rizk und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Gefördert von: Otsuka Pharmaceutical Development and Commercialization.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Division of Nephrology, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham.
  • University of Leicester, Leicester, United Kingdom.
  • Juntendo University Faculty of Medicine, Tokyo.
  • Peking University First Hospital, Beijing.
  • Concord Repatriation General Hospital, Concord, NSW, Australia.
  • Mount Elizabeth Novena Hospital, Singapore.

ORCID-Profile: Vivekanand Jha

Förderung

  • Otsuka Pharmaceutical Development and Commercialization

Zitieren

APA

Rizk, D. V., Barratt, J., Suzuki, Y., Zhang, H., Wong, M. G., Liew, A., Lafayette, R., Tesař, V., Trimarchi, H., Carroll, K., Roberts, I. S. D., Jha, V., Quevedo, A., Han, S. H., Yahya, R., Cheung, C. K., Ramachandran, R., Walsh, M., Chacko, B., …, & VISIONARY Trial Investigators Group (2026). Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609127

Vancouver

Rizk DV, Barratt J, Suzuki Y, Zhang H, Wong MG, Liew A, et al. Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis. New England Journal of Medicine. 2026. doi:10.1056/nejmoa2609127

BibTeX
@article{Rizk2026,
  author = {Rizk, Dana V and Barratt, Jonathan and Suzuki, Yusuke and Zhang, Hong and Wong, Muh Geot and Liew, Adrian and Lafayette, Richard and Tesař, Vladimír and Trimarchi, Hernán and Carroll, Kevin and Roberts, Ian S D and Jha, Vivekanand and Quevedo, Alejandra and Han, Seung Hyeok and Yahya, Rosnawati and Cheung, Chee Kay and Ramachandran, Raja and Walsh, Michael and Chacko, Bobby and Praga, Manuel and Chen, Jin-Bor and Suassuna, José and Xia, Jing and Shah, Lokesh and Perkovic, Vlado and VISIONARY Trial Investigators Group, VISIONARY Trial Investigators Group},
  title = {Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmoa2609127}
}
Kostenlos starten →